Information Provided By: 
Fly News Breaks for August 15, 2018
CRVS, CRVS
Aug 15, 2018 | 11:55 EDT
As previously reported, Credit Suisse analyst Michael Morabito upgraded Corvus Pharmaceuticals to Outperform from Neutral and raised the stock's price target to $15 from $11 after assuming coverage of the name. The analyst believes the company's lead product, CPI-444, has a clear lead in the clinic compared to competitors, and looks like a compelling treatment for PD-1 refractory patients, a growing market with PD-1 therapy being used increasingly in first-line settings.
News For CRVS From the Last 2 Days
There are no results for your query CRVS
